PMID- 36164403
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220928
IS  - 1741-427X (Print)
IS  - 1741-4288 (Electronic)
IS  - 1741-427X (Linking)
VI  - 2022
DP  - 2022
TI  - A Meta-Analysis of Randomized Clinical Trials of Runzao Zhiyang Capsule in 
      Chronic Urticaria.
PG  - 1904598
LID - 10.1155/2022/1904598 [doi]
LID - 1904598
AB  - Chinese herbal medicine has many advantages in the treatment of chronic urticaria 
      (CU). Herein, we evaluated the efficacy and safety of the Runzao Zhiyang (RZZY, 
      Chinese patent herbal medicine capsule) capsule for CU through a meta-analysis of 
      randomized clinical trials (RCTs). This meta-analysis included 17 RCTs involving 
      1,760 patients. RZZY capsule combined with conventional drugs showed a better 
      clinical total effective rate (risk ratio (RR) = 1.20, 95% confidence interval 
      (CI) (1.15, 1.24), P < 0.00001), significantly reduced the adverse reaction rate 
      [RR = 0.68, 95% CI (0.50, 0.92), P=0.01] and recurrence rate [RR = 0.29, 95% CI 
      (0.18, 0.46), P < 0.00001], and improved the life quality of patients (mean 
      difference (MD) = -2.95, 95% CI (-4.32, -1.57), P=0.0001). Meanwhile, the serum 
      Interleukin-4 (IL-4) (MD = -13.83, 95% CI (-23.45, -4.20), P=0.005) and 
      immunoglobulin E (IgE) (MD = -22.99, 95% CI (-31.48, -14.50), P < 0.00001) of 
      patients in the intervention group decreased more significantly. In all, the RZZY 
      capsule has potential therapeutic advantages and is relatively safe for CU. 
      However, we are cautious about the conclusion, which needs to be further 
      confirmed by more large samples, multicenter, and high-quality research in the 
      later stage.
CI  - Copyright (c) 2022 Shengzhen Ye et al.
FAU - Ye, Shengzhen
AU  - Ye S
AD  - Chengdu University of Traditional Chinese Medicine, Chengdu 610075, Sichuan 
      Province, China.
AD  - Affiliated Hospital of Chengdu University of Traditional Chinese Medicine, 
      Chengdu 610072, Sichuan Province, China.
FAU - Zhang, Xueer
AU  - Zhang X
AD  - Chengdu University of Traditional Chinese Medicine, Chengdu 610075, Sichuan 
      Province, China.
AD  - Affiliated Hospital of Chengdu University of Traditional Chinese Medicine, 
      Chengdu 610072, Sichuan Province, China.
FAU - Ling, Guihua
AU  - Ling G
AD  - Chengdu University of Traditional Chinese Medicine, Chengdu 610075, Sichuan 
      Province, China.
AD  - Affiliated Hospital of Chengdu University of Traditional Chinese Medicine, 
      Chengdu 610072, Sichuan Province, China.
FAU - Xiao, Xianjun
AU  - Xiao X
AD  - Chengdu University of Traditional Chinese Medicine, Chengdu 610075, Sichuan 
      Province, China.
FAU - Huang, Dan
AU  - Huang D
AD  - Chengdu University of Traditional Chinese Medicine, Chengdu 610075, Sichuan 
      Province, China.
AD  - Affiliated Hospital of Chengdu University of Traditional Chinese Medicine, 
      Chengdu 610072, Sichuan Province, China.
FAU - Chen, Mingling
AU  - Chen M
AUID- ORCID: 0000-0002-8879-0857
AD  - Affiliated Hospital of Chengdu University of Traditional Chinese Medicine, 
      Chengdu 610072, Sichuan Province, China.
LA  - eng
PT  - Journal Article
DEP - 20220917
PL  - United States
TA  - Evid Based Complement Alternat Med
JT  - Evidence-based complementary and alternative medicine : eCAM
JID - 101215021
PMC - PMC9509263
COIS- The authors declare that they have no conflicts of interest.
EDAT- 2022/09/28 06:00
MHDA- 2022/09/28 06:01
PMCR- 2022/09/17
CRDT- 2022/09/27 01:57
PHST- 2022/05/25 00:00 [received]
PHST- 2022/08/11 00:00 [revised]
PHST- 2022/08/26 00:00 [accepted]
PHST- 2022/09/27 01:57 [entrez]
PHST- 2022/09/28 06:00 [pubmed]
PHST- 2022/09/28 06:01 [medline]
PHST- 2022/09/17 00:00 [pmc-release]
AID - 10.1155/2022/1904598 [doi]
PST - epublish
SO  - Evid Based Complement Alternat Med. 2022 Sep 17;2022:1904598. doi: 
      10.1155/2022/1904598. eCollection 2022.